118 related articles for article (PubMed ID: 21458889)
1. [Immunosuppression in liver transplantation: renoprotective regimens].
Serrano Aulló MT; Parra Moncasi E; Lorente Pérez S
Gastroenterol Hepatol; 2011; 34(6):422-7. PubMed ID: 21458889
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
3. Initial immunosuppression in liver transplant recipients with impaired renal function.
Varo E; López A; Rivero C
Transplant Proc; 2005 Nov; 37(9):3909-12. PubMed ID: 16386581
[TBL] [Abstract][Full Text] [Related]
4. Hot-topic debate on kidney function: renal-sparing approaches are beneficial.
Durand F
Liver Transpl; 2011 Nov; 17 Suppl 3():S43-9. PubMed ID: 21796759
[TBL] [Abstract][Full Text] [Related]
5. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?
Beckebaum S; Cicinnati VR; Radtke A; Kabar I
Liver Int; 2013 May; 33(5):656-65. PubMed ID: 23442173
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
8. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
9. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation.
Saner FH; Cicinnati VR; Sotiropoulos G; Beckebaum S
Liver Int; 2012 Feb; 32(2):179-88. PubMed ID: 21745304
[TBL] [Abstract][Full Text] [Related]
10. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.
Thölking G; Siats L; Fortmann C; Koch R; Hüsing A; Cicinnati VR; Gerth HU; Wolters HH; Anthoni C; Pavenstädt H; Suwelack B; Schmidt HH; Kabar I
Ann Transplant; 2016 Mar; 21():167-79. PubMed ID: 27003330
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
Guerra G; Srinivas TR; Meier-Kriesche HU
Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
[TBL] [Abstract][Full Text] [Related]
13. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
Arora-Gupta N; Davies P; McKiernan P; Kelly DA
Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
[TBL] [Abstract][Full Text] [Related]
14. Renal-sparing strategies in cardiac transplantation.
Gustafsson F; Ross HJ
Curr Opin Organ Transplant; 2009 Oct; 14(5):566-70. PubMed ID: 19542890
[TBL] [Abstract][Full Text] [Related]
15. Current immunosuppressive approaches in liver transplantation.
Iacob S; Cicinnati VR; Beckebaum S
Panminerva Med; 2009 Dec; 51(4):215-25. PubMed ID: 20195232
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
Baran DA; Galin ID; Gass AL
Am J Cardiovasc Drugs; 2004; 4(1):21-9. PubMed ID: 14967063
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: maintenance immunosuppression in kidney transplant recipients.
Samaniego M; Becker BN; Djamali A
Nat Clin Pract Nephrol; 2006 Dec; 2(12):688-99. PubMed ID: 17124526
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
19. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
20. Conversion to everolimus in maintenance patients--current clinical strategies.
Pohanka E
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
